The R&D heads of over 25 global biopharmaceutical companies have signed a joint letter expressing alarm over the impact of the Biden administration's new prescription medicine price negotiation power.
Global R&D heads sign joint letter expressing alarm over new pricing power
October 20, 2023 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Week in Review' Podcast - 27 February
February 27, 2026 - - Podcast -
EU backs Australian-led consortium with up to $250m to advance next-generation influenza vaccines
February 26, 2026 - - Latest News -
United front forms across Asia Pacific to change the future of Pulmonary Arterial Hypertension
February 26, 2026 - - Latest News -
There are, in effect, two Pharmaceutical Benefits Schemes operating in Australia today
February 26, 2026 - - Latest News -
Reading the room on reform might mean following the Budget message
February 25, 2026 - - Latest News -
Weight-loss medicines approved in New Zealand, and recommended for funding, but pathway remains unclear
February 25, 2026 - -
Neurizon advances ALS drug program as funding, trials and global partnerships gain momentum
February 25, 2026 - - Australian Biotech

